Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

Study acronym: PRESERVE
StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 12 → 20 locations
  2. Eligibility criteria expanded, about 3 words
  3. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A study of ALV-100 to assess efficacy, safety and tolerability among participants with overweight or obesity who have previously achieved a body weight reduction of ≥10% while treated with incretin-based therapies.
Trial Details
NCT Number NCT07837973
Lead Sponsor Alveus Therapeutics, Inc.
Conditions
(from sponsor)		 Overweight , Obesity, Adults
Related terms Obesity, Overweight
Enrollment 220 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov